# A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

> **NCT06283121** · PHASE2 · NOT_YET_RECRUITING · sponsor: **China Medical University, China** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer, Metastatic

## Interventions

- **BIOLOGICAL:** BioTTT001 intraperitoneal infusion
- **DRUG:** SOX regimen
- **DRUG:** toripalimab

## Key facts

- **NCT ID:** NCT06283121
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-02
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06283121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06283121, "A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06283121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*